BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
BioAdaptives Inc. BDPT
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$18,278
▲ 44.3% vs FY2024
EPS · FY25
$-0.15
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-8523.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 18,278.00
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 8523 cents on every revenue dollar this year.
Per share
USD -0.15
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-5701.8%
Net margin-8523.4%
Return on assets-638.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.1%
+2.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+63.5%
Change, 10 years—
The share count grew 64% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 225,901.00
total assets, end of FY2025
Total assetsUSD 225,901.00
EquityUSD -2.1M
CashUSD 215,205.00
Gross debtUSD 32,096.00
Net debtUSD -183,109.00
Current ratio0.09×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
·
·
·
·
·
·
−0.0
−0.0
Income tax $B
0.0
0.0
·
0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.15
−0.11
·
·
·
−0.04
−0.01
−0.08
−0.02
−0.21
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
Shares out B
0.01
0.00
0.01
0.25
0.05
0.02
0.02
0.02
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
35 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed